Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGUE: Aprepitant for CINV in HAIC-Treated HCC
NCT05711823Phase 3Not yet recruiting
- Sponsor
- Guangxi Medical University
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Guangxi Medical University. Primary endpoint: Complete response rate at 3 weeks. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05711823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711823.